<?xml version="1.0" encoding="UTF-8"?>
<results title="drug">
 <result pre="viral entry, as inhibition of TMPRSS2 with serine protease inhibitor" exact="camostat" post="mesylate blocks entry of SARS-CoV-2 into the epithelial cells"/>
 <result pre="infection with viruses similar to SARS-CoV-2 [48]. Camostat mesylate and" exact="nafamostat" post="mesylate are serine protease inhibitors, which are commercially available"/>
 <result pre="pancreatitis and cystic fibrosis, respectively. Preclinical studies show treatment with" exact="camostat" post="mesylate blocks entry of SARS-CoV-2 into the epithelial cells"/>
 <result pre="blocks entry of SARS-CoV-2 into the epithelial cells [12]. Likewise," exact="nafamostat" post="has been reported to reduce TMPRSS2-dependent fusion of MERS-CoV"/>
 <result pre="to case reports suggesting clinical efficacy [50]. Potential efficacy of" exact="camostat" post="and the more potent nafamostat in the treatment of"/>
 <result pre="efficacy [50]. Potential efficacy of camostat and the more potent" exact="nafamostat" post="in the treatment of patients with COVID-19 is being"/>
 <result pre="SARS-CoV-2 entry into the host cells, anti-androgenic agents, such as" exact="bicalutamide" post="and enzalutamide are being tested in prospective phase 2"/>
 <result pre="into the host cells, anti-androgenic agents, such as bicalutamide and" exact="enzalutamide" post="are being tested in prospective phase 2 clinical trials"/>
 <result pre="others. There has been considerable interest in the use of" exact="chloroquine" post="and its less toxic version hydroxychloroquine, because of the"/>
 <result pre="[51]). However, the initial enthusiasm for the potential efficacy of" exact="hydroxychloroquine" post="(alone or in combination with azithromycin) in the treatment"/>
 <result pre="trials [52]. There were no beneficial effects of treatment with" exact="hydroxychloroquine" post="in the Randomised Evaluation of COVID-19 Therapy (RECOVERY) study"/>
 <result pre="(Table 1 ), which randomized 1,542 hospitalized patients to the" exact="hydroxychloroquine" post="and 3,132 patients to the usual care (https://www.recoverytrial.net/results/hydroxychloroquine-results). The"/>
 <result pre="to the usual care (https://www.recoverytrial.net/results/hydroxychloroquine-results). The 28-day mortality in the" exact="hydroxychloroquine" post="group was 25.7% as compared to 23.5% in the"/>
 <result pre="randomized clinical trials are still ongoing to test efficacy of" exact="hydroxychloroquine" post="in the treatment of patients with COVID-19. Table 1"/>
 <result pre="(95% CI: 0.67-0.96)No benefit in those not requiring respiratory support" exact="Hydroxychloroquine" post="(HCQ) Viral entry by endocytosis Impairs lysosome function HCQ:"/>
 <result pre="RNA synthesis upon incorporation. Among the nucleoside analogues, remdesivir, an" exact="adenosine" post="analogue, which was originally developed for treatment of Ebola"/>
 <result pre="requiring respiratory support in the RECOVERY study [69]. Thus far," exact="dexamethasone" post="is the only drug shown to reduce COVID-19 mortality"/>
 <result pre="for influenza H1N1 virus pathogenesis in micePLoS Pathog92013e1003774 49YamamotoMMatsuyamaSLiXTakedaMKawaguchiYInoueJIIdentification of" exact="nafamostat" post="as a potent inhibitor of middle east respiratory syndrome"/>
 <result pre="cell-cell fusion assayAntimicrob Agents Chemother6020166532653927550352 50JangSRheeJY.Three cases of treatment with" exact="nafamostat" post="in elderly patients with COVID-19 pneumonia who need oxygen"/>
 <result pre="of chloroquine/hydroxychloroquine for COVID-19J Crit Care59202017619032683212 52CavalcantiABZampieriFGRosaRGAzevedoLCPVeigaVCAvezumAHydroxychloroquine with or without" exact="Azithromycin" post="in Mild-to-Moderate Covid-19N Engl J Med2020, NEJMoa2019014 53ChorinEDaiMShulmanEWadhwaniLBar-CohenRBarbhaiyaCThe QT"/>
 <result pre="NEJMoa2019014 53ChorinEDaiMShulmanEWadhwaniLBar-CohenRBarbhaiyaCThe QT interval in patients with COVID-19 treated with" exact="hydroxychloroquine" post="and azithromycinNat Med26202080880932488217 54WangQWuJWangHGaoYLiuQMuAStructural basis for RNA replication by"/>
</results>
